within Pharmacolibrary.Drugs.ATC.C;

model C01BG11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0018,
    k12             = 0.44,
    k21             = 0.44
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01BG11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vernakalant is an antiarrhythmic agent primarily used for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. It acts as a multichannel blocker and is approved for intravenous use in Europe, Canada, and several other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with atrial fibrillation following intravenous administration.</p><h4>References</h4><ol><li><p>Finnin, M (2010). Vernakalant: A novel agent for the termination of atrial fibrillation. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 67(14) 1157–1164. DOI:<a href=&quot;https://doi.org/10.2146/ajhp080501&quot;>10.2146/ajhp080501</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20592320/&quot;>https://pubmed.ncbi.nlm.nih.gov/20592320</a></p></li><li><p>Naccarelli, GV, et al., &amp; Gonzalez, MD (2008). Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation. <i>Expert opinion on investigational drugs</i> 17(5) 805–810. DOI:<a href=&quot;https://doi.org/10.1517/13543784.17.5.805&quot;>10.1517/13543784.17.5.805</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18447605/&quot;>https://pubmed.ncbi.nlm.nih.gov/18447605</a></p></li><li><p> (2007). Vernakalant: RSD 1235, RSD-1235, RSD1235. <i>Drugs in R&amp;D</i> 8(4) 259–265. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200708040-00007&quot;>10.2165/00126839-200708040-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17596113/&quot;>https://pubmed.ncbi.nlm.nih.gov/17596113</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01BG11;
